Boston Pharmaceutical / Pharmacy Conference Boston, USA

Final Agenda: Track 9 will explore innovative methods, approaches and technologies that pharmaceutical and biotechnology organizations are utilizing for collaborative drug design, knowledge management and translational medicine. New paradigms in drug discovery will also be addressed...more

The 2012 Expo plans to unite 2,000+ life sciences, pharmaceutical, clinical, healthcare, and IT professionals from 30+ countries. The Expo provides the perfect venue to share information and discuss enabling technologies that are driving biomedical research and the drug development process. Since its debut in 2002, the annual Bio-IT World Conference & Expo has established itself as a premier event showcasing the myriad applications of IT and informatics to biomedical research and the drug ...more

he field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market.  There still remain a number of challenges that include reducing immunogenicity, improving the targeting in solid tumors, and increasing the ability to kill cancer cells.  The pre-clinical and clinical results of recent new constructs will be shared, and the changes in regulation of antibodies will be reviewed.  The latest new ...more

Discover how your research can benefit by joining us next year at the Boston Park Plaza Hotel on April 30-May 4, 2012. Experience for yourself what the buzz is about.If you were not able to attend this year’s PEGS event, purchase a CD to get access to more than 230 presentations from thought leaders in the field....more

Many recent pharmaceutical advances are based on detailed knowledge and characterization of the underlying proteins involved. Many companies are working to meet those demands through new tools, technologies, and assays. More important than the tools themselves is the hard work of applying the technologies appropriately to each situation and evolving a true analytical strategy...more

Protein Aggregation and Stability in Biopharmaceutical Products May 2 - 3 The study and prevention of protein aggregation and its consequences represents one of the most demanding tasks in biomedical research and pharmaceutical manufacturing today. Whether one’s interests lie in protein characterization or analytics, the study of protein aggregation-induced adverse effects or immunogenicity, or work in formulation and process development for protein-based therapeutics, “Protein Aggregation and ...more

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.  These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical ...more

AdvaMed 2011 attracts an international audience and as such, we welcome proposals addressing international medical technology subjects. We also warmly welcome proposals that include (or specifically target) diagnostics-related, as well as medical information technology, issues and trends. AdvaMed 2011 conference program committee encourages and welcomes panel submissions addressing timely, relevant, novel, and insightful topics that feature expert and dynamic speakers. Among other ...more